Back to search
FDAFDA · Food and drugs·Recall number D-0859-2016

Amikacin Sulfate injection USP,1 gm/4 mL (250 mg/mL) 4mL vial, Rx only, Manufactured in Hungary For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454. Individual Pack NDC 0703-9040-01, Shelf Pack NDC 0703-9040-03

Published June 1, 2016 · Recall initiated: March 9, 2016

Summary

FDA records drug Class I recall D-0859-2016, published June 1, 2016 and initiated March 9, 2016. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 6,291 units; Lot: Lot #: 4750915, Exp 9/2017. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter: particulate matter identified as glass in one vial.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide and Puerto Rico
Lot
Lot #: 4750915, Exp 9/2017
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Amikacin Sulfate injection USP,1 gm/4 mL (250 mg/mL) 4mL vial, Rx only, Manufactured in Hungary For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454. Individual Pack NDC 0703-9040-01, Shelf Pack NDC 0703-9040-03 recalled?

Yes. FDA published recall D-0859-2016 on June 1, 2016. Reported hazard: Presence of Particulate Matter: particulate matter identified as glass in one vial.

What should I do if I have this product?

Voluntary: Firm initiated · Letter